Updated: Multiple Biosimilars To Avastin Have Launched In EU
Industry Had Expected June Roll-Out
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
You may also be interested in...
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.
Pfizer is on course for a major milestone for biosimilars this year, as it continues to make plans for the separation of its off-patent and mature brands unit, Upjohn, ahead of its merger with Mylan.